These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1513800)

  • 21. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
    Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
    Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
    J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Faure N; Lemay A
    Clin Endocrinol (Oxf); 1987 Dec; 27(6):703-13. PubMed ID: 3138052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buserelin as primary therapy in advanced prostatic carcinoma.
    Presant CA; Soloway MS; Klioze SS; Kosola JW; Yakabow AL; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Ford KS
    Cancer; 1985 Nov; 56(10):2416-9. PubMed ID: 3930064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclical breast pain and swelling in relation to differing patterns of suppression of ovarian activity with the luteinizing hormone-releasing hormone analogue buserelin acetate: case report.
    Magill P; Barlow D
    Fertil Steril; 1995 Jan; 63(1):193-5. PubMed ID: 7805912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Lemay A; Quesnel G
    Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follicle stimulating hormone-secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration.
    Damjanović S; Micić D; Popović V; Petakov M; Kendereski A; Sumarac M; Manojlović D; Mićić J
    J Endocrinol Invest; 1991 Apr; 14(4):299-304. PubMed ID: 1713932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of LH-RH analogue in patients with benign prostatic hyperplasia.
    Lukkarinen O
    Urology; 1991 Feb; 37(2):92-4. PubMed ID: 1704161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma.
    Kouri M; Pyrhönen S; Kuusela P
    J Surg Oncol; 1992 Feb; 49(2):78-85. PubMed ID: 1738240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Value of the tumor markers CA 125, Ca 19-9, CA 15-3 and CEA in endometriosis].
    Cirkel U; Ochs H; Latussek B; Schneider HP
    Geburtshilfe Frauenheilkd; 1991 Aug; 51(8):626-31. PubMed ID: 1936874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
    Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis].
    Jurkowska G; Kulpa J; Skrodzka D; Rogowski F
    Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.